Sizing Up Syros Pharmaceuticals [Seeking Alpha]
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Seeking Alpha
SummaryToday, we revisit Syros Pharmaceuticals, a Tier 4 name we have not covered in about a year.The stock is about where it was a year ago when we originally took a look at it.We provide an analysis of Syros and update our investment view based on recent events at the company in the paragraphs below.The company in bars is, I have noticed, either very good or very bad; there seems to be some force of a minor destiny that draws good company to the same place at the same timeToday, we revisit aCompany OverviewSyros Pharmaceuticals (SYRSSource: Company PresentationPipeline:SY-1425:SY-1425 is an oral first-in-class selective retinoic acid receptor alpha agonist. The company believes the asset has real potential as a combination agent for patients with acute myeloid leukemia. The company used their platform to discover a subset of AML patients with a highly specialized regulatory region of the DNA, known as a super-enhancer, associated with the RARA gene. Furthermore, they developed a bio
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML [Yahoo! Finance]Yahoo! Finance
- Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression [Yahoo! Finance]Yahoo! Finance
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionBusiness Wire
SYRS
Earnings
- 3/27/24 - Miss
SYRS
Analyst Actions
- 4/1/24 - HC Wainwright
SYRS
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- SYRS's page on the SEC website